diphosphoglycerate levels, which lead to more efficient oxygen transport and unloading. 2 In the present article, we review the current medical literature on methemoglobinemia with a focus on lidocaine, as its particular incidence appears to be both uncommon and underreported.
Symptoms and Risk
Methemoglobinemia symptoms range from anxiety to cyanosis to cardiac arrhythmias. 3 Generally, higher levels of MetHb lead to more severe symptoms and higher risk of morbidity and mortality (Table) . 2, 3 However, MetHb levels as high as 81.5% have been reported with full resolution of symptoms after treatment. 4 In addition, MetHb levels are not always associated with symptom severity.
In a prospective study of patients receiving fiberoptic bronchoscopy with topical lidocaine anesthesia, De 5 reported no correlation between symptom severity scores, MetHb levels, or amount of lidocaine used. Palpitation was the most common symptom.
Certain patient populations are at higher risk for methemoglobinemia and warrant careful monitoring by clinicians. For example, comorbidities that impair oxygen transport, including anemia, heart disease, and pulmonary disease (chronic obstructive pulmonary disease, pneumonia), predispose patients to methemoglobinemia.
Symptom development is thought to be related to a preexisting inability to buffer oxidant stress. 6 Patients with liver cirrhosis must also be closely monitored. The red blood cells in patients with cirrhosis are already under extreme oxidative stress; therefore, any further increase in oxidative stress may lead to methemoglobinemia. 7 Similarly, neonates often have underdeveloped hepatic and renal function and are at increased risk for methemoglobinemia.
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In addition, clinicians should closely monitor patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency.
As methylene blue uses the nicotinamide adenine dinucleotide phosphate (NADPH)-MetHb reductase system (in which G6PD is a major cofactor), patients with G6PD deficiency are unable to respond to methylene blue. 
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Benzocaine, prilocaine, and dapsone are among the most commonly studied oxidants. Prilocaine, a common anesthetic in dental procedures, appears to be the most potent topical anesthetic to cause methemoglobinemia. 12 Sambrook et al 13 looked at 221 adverse reactions to dental local anesthetics and found that prilocaine was used in 59% of all cases and in all 6 cases of methemoglobinemia.
In a separate study 14 of 242 cases of methemoglobinemia, 60.7% of cases were associated with dental procedures.
Currently, few systemic reports of methemoglobinemia in a hospital setting exist. One such report 15 of hemoglobin unable to bind oxygen. 7 Acquired forms of methemoglobinemia are much more common 6 and are a result of exposure to a long list of common oxidants ( Figure) , most notably nitrates, chlorates, aniline compounds, benzocaine, and dapsone. tial. 18 Although the exact prevalence of methemoglobinemia is unknown, these compounds are well-documented causes of the disorder.
Lidocaine-Induced Methemoglobinemia
Lidocaine is an amino-amide drug typically injected subcutaneously or applied topically for procedures such as esophagogastroduodenoscopy and fiberoptic bronchoscopy. Likewise, clinicians may have a lower threshold for administration of methylene blue in patients with comorbidities described previously.
Methemoglobinemia is a potentially fatal condition that, although generally rare, must be part of the differential diagnosis for any patient exhibiting clinical signs of hypoxia, cyanosis, or depressed pulse oximetry readings or who has been exposed to a substance with strong oxidative potential. As methemoglobinemia may occur even at manufacturer-specified doses of oxidative compounds, no specific method of preventing this condition currently exists, and clinical prowess is the best tool clinicians have for preventing complications. Physicians who commonly use oxidant compounds such as lidocaine should identify factors in their patients that put them at increased risk of developing methemoglobinemia. Additional research is needed to identify the minimum dosage at which lidocaine is a risk for methemoglobinemia.
